CEO Cary Claiborne signs new 3-year deal at Adial; bonus target raised to 50%, 350K option grant

ADIAL PHARMACEUTICALS, INC.

New three-year employment agreement effective Dec 5, 2024, replaces prior agreement from Dec 2021.
Base salary remains $489,250; annual bonus target increased to 50% of base salary.
Granted 350,000 stock options vesting pro rata monthly over 36 months.
Agreement provides for severance and change-in-control protections per detailed terms.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.